Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06873555 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

Name: A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors — clinical trial record (NCT06873555)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorHeronova Pharmaceuticals

Started2024-09-11

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 15 months later Aug 2026 → Dec 2027

See other at-risk trials from Heronova Pharmaceuticals

Amendment history

2026-09-17

Primary completion pushed: 2026-08 → 2027-12

Completion pushed: 2026-08 → 2027-12

2025-03-16

Study Status, Arms and Interventions, Contacts/Locations v1

Study sitesdetails revised at 1 of 2 sites

2025-03-07

Original filing

Heronova Pharmaceuticals

3 trials monitored

See 1 trial at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

Small Cell Lung Cancer

539 trials monitored

See 30 trials at risk

This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.

Trial Details

NCT Number	NCT06873555
Lead Sponsor	Heronova Pharmaceuticals
Conditions	Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
Enrollment	60 participants
Start Date	2024-09-11
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-16